Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Justicia adhatoda contains vasicine as its primary bioactive alkaloid, which acts as a bronchodilator and expectorant. This Ayurvedic herb demonstrates respiratory benefits through smooth muscle relaxation and reduced mucus viscosity in the airways.
Origin & History
Justicia adhatoda, known as Adaaodai in Siddha medicine, is a perennial shrub native to India, Sri Lanka, and Southeast Asia, now cultivated in China, Cuba, and Ethiopia. The plant's leaves are primarily used medicinally and are prepared as traditional decoctions (kudineer), methanolic extracts, powders, juices, and syrups. This alkaloid-rich herb from the Acanthaceae family features quinazoline alkaloids like vasicine as its primary active constituents.
Research Narrative (Provisional)
Clinical evidence for Justicia adhatoda is limited, with no large-scale RCTs or meta-analyses identified. A 2015 Indian Chest Society trial (PMID not available) on leaf extract in chronic bronchitis showed respiratory improvements, while a double-blind study using vasicine-rich extract reported modest FEV1 improvements in asthma patients. Most supporting data derives from in vitro research, such as anticancer studies (PMC9737760), with human clinical trials notably absent.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Adaaodai Kudineer (Justicia adhatoda) is a medicinal herb used primarily for its bioactive alkaloid content rather than conventional macronutrient density. Key bioactive compounds include: Vasicine (peganine) as the primary quinazoline alkaloid at approximately 0.5–1.5% dry weight concentration in leaves, which is the principal bronchodilatory compound; Vasicinone at approximately 0.07–0.1% dry weight, a metabolite of vasicine with documented bronchodilatory and antihistaminic activity; Vasicinol and deoxyvasicine present in trace quantities (<0.05% dry weight). Secondary phytochemicals include flavonoids (quercetin, kaempferol glycosides) at approximately 1.2–2.4% total flavonoid content by dry weight, and saponins at approximately 0.8–1.2% dry weight. Phenolic acid content estimated at 15–25 mg gallic acid equivalents per gram dry leaf. Tannin content is approximately 2–4% dry weight. Regarding conventional nutrients: crude protein content in dried leaf is approximately 15–18% dry weight with limited bioavailability due to tannin-protein binding interactions; crude fiber approximately 18–22% dry weight; ash content approximately 8–12% dry weight indicating moderate mineral presence including calcium (estimated 1.2–1.8 g/100g dry weight), potassium (approximately 1.5–2.0 g/100g dry weight), iron (approximately 28–35 mg/100g dry weight), and magnesium (approximately 180–220 mg/100g dry weight). Vitamin C content in fresh leaves is approximately 30–50 mg/100g fresh weight but degrades significantly upon drying and decoction preparation. Essential oils constitute approximately 0.02–0.05% of leaf dry weight. Bioavailability note: Vasicine absorption is enhanced in aqueous decoction (kudineer) form due to heat-mediated extraction efficiency, estimated at 60–75% of total alkaloid content extractable via standard boiling preparation; tannin content may inhibit iron and protein bioavailability when consumed as a decoction with food.
Reported Mechanism (Provisional)
Vasicine alkaloids in Justicia adhatoda activate beta-2 adrenergic receptors, causing bronchial smooth muscle relaxation and airway dilation. The compounds also inhibit histamine release from mast cells while reducing mucus viscosity through mucolytic enzyme activation. Vasicinone, another key alkaloid, enhances ciliary action to promote expectoration.
Clinical Narrative (Provisional)
Limited clinical evidence includes one small uncontrolled study showing reduced cough frequency and sputum thickness in chronic bronchitis patients within 7-14 days of treatment. A single double-blind trial reported 15% improvement in FEV1 measurements in mild-to-moderate asthma patients, though sample size was not specified. The overall clinical evidence remains preliminary with small study populations. More robust randomized controlled trials are needed to establish definitive therapeutic efficacy.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.